Cytokinetics (CYTK)

P/S ratio as of October 2026 (TTM): 130

According to Cytokinetics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -50.7. At the end of 2026 the company had a P/S ratio of 165.

P/S ratio history for Cytokinetics from 2004 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	165	92.36%
2025	85.7	-71.66%
2024	303	-72.17%
2023	> 1000	2271.65%
2022	45.8	-16.07%
2021	54.6	107.32%
2020	26.3	12.75%
2019	23.4	112.85%
2018	11.0	-66.58%
2017	32.9	608.37%
2016	4.64	-67.9%
2015	14.4	118.99%
2014	6.60	1.38%
2013	6.51	-47.69%
2012	12.4	-28.3%
2011	17.3	-68.04%
2010	54.3	2382.3%
2009	2.19	-80.92%
2008	11.5	-33.03%
2007	17.1	-83.47%
2006	104	425.56%
2005	19.7	-3.76%
2004	20.5

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Amgen AMGN	6.54	-94.97%	🇺🇸 USA
Trevena TRVN	0.0176	-99.99%	🇺🇸 USA
Ligand Pharmaceuticals LGND	21.8	-83.26%	🇺🇸 USA
Acorda Therapeutics ACOR	0.0071	-99.99%	🇺🇸 USA
Array Technologies ARRY	0.4627	-99.64%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Cytokinetics (CYTK)

P/S ratio as of October 2026 (TTM): 130